Skip to content
stoqly

Integra Lifesciences

IART Nasdaq Health Care Equipment Financials FY2016–FY2025

Integra Lifesciences' revenue rose 1.5% to $1.6 billion in fiscal 2025. Its operating margin was −30.2%, down from 1.8% a year earlier. Free cash flow was −$31 million, against $25 million a year earlier. It paid out $0 million in dividends and buybacks. The diluted share count fell 0.4%.

Last close · Oct 23, 2026

$11.91

3.4%
Value it Compare
Revenue Total sales reported in the income statement.
$1.6B
1.5% vs prior year
Operating margin Operating income as a share of revenue.
−30.2%
31.9 pts
Net income Profit after all expenses, interest and tax.
−$517M
Free cash flow Cash from operations minus capital spending.
−$31.1M
224.4%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
−22.0%
23.1 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$936M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
70.1x
On $0.17 EPS (TTM)

About these figures. Integra Lifesciences' 2025 operating loss (about US$493 million) leaves its earnings before interest, tax, depreciation and amortization negative, so net debt to EBITDA is blank for that year.

What Integra Lifesciences does

No business description yet.

Legal name
INTEGRA LIFESCIENCES HOLDINGS CORP
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0000917520-26-000011
0000917520

Revenue and margins

Integra Lifesciences had $1.6B of revenue in fiscal 2025, up 1.5% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$31.1M in fiscal 2025, −1.9% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Integra Lifesciences returned $0.2M to shareholders in fiscal 2025. The diluted share count fell 0.4%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Integra Lifesciences yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$463M and divides by 76.7M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 70.1x · peers 33.6x · sector 27.9x.

Balance sheet

Cash, debt and the ratios that show how comfortably Integra Lifesciences can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $513M$457M$309M$274M$264M
Debt incl. finance leases $844M$775M$775M$761M$727M
Net debt / EBITDA 1.3x1.1x2.8x5.3x—
Debt / equity 0.5x0.4x0.5x0.5x0.7x
Interest coverage 3.9x4.8x2.2x0.4x−5.7x
Current ratio 3.4x3.6x3.5x1.2x2.5x
Quick ratio 2.5x2.6x2.2x0.7x1.5x
Total assets $3.8B$3.9B$3.8B$4.0B$3.6B
Total liabilities $2.1B$2.1B$2.2B$2.5B$2.6B
Shareholders' equity $1.7B$1.8B$1.6B$1.5B$1.0B
Net debt (− = net cash) $330M$318M$466M$487M$463M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.1M

1 insider

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

DateInsiderTradeSharesPriceValueFiling
Nov 5, 2025 Jeffrey A GravesDirector Bought 9,000 $11.35 $0.1M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✕ ✕
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✕ ✕ ✕
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✕ ✓ ✓
Current ratio rose ✕ ✕ ✓
Share count didn't rise ✓ ✓ ✓
Gross margin rose ✕ ✕ ✕
Revenue rose relative to assets ✕ ✓ ✕
F-score 4 / 95 / 95 / 9
Accruals ratio −1.9%−3.5%−14.8%
Altman Z'' 3.081.721.17

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Integra Lifesciences IART $936M 1.5% −30.2% −1.9% −22.0% 70.1x 5
Integer ITGR $4.3B 8.0% 11.9% 5.7% 6.6% 34.7x 7 Compare →
Penumbra PEN $12.8B 17.5% 13.5% 12.5% 18.8% 79.7x 7 Compare →
LivaNova LIVN $4.6B 10.7% 14.4% 12.5% 12.8% 23.9x 5 Compare →
CONMED CNMD $1.5B 5.2% 7.5% 11.0% 3.7% — 6 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $992M $1.2B $1.5B $1.5B $1.4B $1.5B $1.6B $1.5B $1.6B $1.6B
Gross profit $643M $753M $901M $953M $851M $945M $970M $885M $882M $832M
Research and development $58.2M $63.5M $78.0M $79.6M $77.4M $93.1M $101M $104M $115M $99.0M
Operating income $115M $44.8M $111M $93.8M $151M $197M $239M $112M $28.4M −$493M
Interest expense $25.8M $35.0M $64.7M $54.0M $71.6M $50.4M $49.6M $51.4M $70.6M $86.3M
Pretax income $90.4M $11.4M $57.4M $60.1M $93.5M $215M $214M $81.1M −$18.2M −$564M
Income tax $15.8M −$53.4M −$3.4M $9.9M −$40.4M $45.6M $33.3M $13.3M −$11.3M −$47.0M
Net income $74.6M $64.7M $60.8M $50.2M $134M $169M $181M $67.7M −$6.9M −$517M
Diluted EPS $0.94 $0.82 $0.72 $0.58 $1.57 $1.98 $2.16 $0.84 −$0.09 −$6.74
Diluted shares 0.08B 0.08B 0.08B 0.09B 0.09B 0.09B 0.08B 0.08B 0.08B 0.08B
Cash flow
Cash from operations $116M $115M $200M $231M $204M $312M $265M $140M $129M $50.4M
Capital expenditure $47.3M $43.5M $77.7M $69.5M $38.9M $48.0M $42.3M $66.9M $104M $81.4M
Free cash flow $69.1M $71.0M $122M $162M $165M $264M $222M $73.1M $25.0M −$31.1M
Depreciation and amortization $72.7M $88.9M $111M $110M $69.9M $56.3M $54.0M $53.3M $63.7M $59.8M
Stock-based compensation $17.3M $21.6M $20.8M $21.3M $19.6M $36.2M $27.7M $20.1M $24.4M $18.6M
Acquisitions $0.2M $1.2B $26.7M $30.5M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Share buybacks $0.0M $0.0M $0.0M $0.0M $100M $0.0M $125M $275M $52.5M $0.2M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $0.0M $0.0M $0.0M $0.0M $100M $0.0M $125M $275M $52.5M $0.2M
Balance sheet
Cash and short-term investments $102M $175M $139M $199M $470M $513M $457M $309M $274M $264M
Total debt $0.0M $0.0M $900M $878M $878M $844M $775M $775M $761M $727M
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Current assets $495M $822M $775M $858M $1.2B $1.2B $1.2B $1.1B $1.1B $1.2B
Current liabilities $124M $349M $263M $331M $401M $340M $321M $307M $922M $456M
Inventory $217M $296M $280M $316M $310M $317M $325M $390M $429M $493M
Property and equipment, net $222M $269M $300M $337M $288M $312M $311M $340M $406M $444M
Total assets $1.8B $3.2B $3.1B $3.3B $3.6B $3.8B $3.9B $3.8B $4.0B $3.6B
Total liabilities $968M $2.2B $1.7B $1.9B $2.1B $2.1B $2.1B $2.2B $2.5B $2.6B
Shareholders' equity $840M $962M $1.4B $1.4B $1.5B $1.7B $1.8B $1.6B $1.5B $1.0B
Margins
Gross margin 64.8% 63.4% 61.2% 62.8% 62.0% 61.2% 62.3% 57.4% 54.8% 50.9%
Operating margin 11.6% 3.8% 7.5% 6.2% 11.0% 12.8% 15.3% 7.2% 1.8% −30.2%
EBITDA margin 19.0% 11.3% 15.1% 13.4% 16.1% 16.4% 18.8% 10.7% 5.7% −26.5%
Net margin 7.5% 5.5% 4.1% 3.3% 9.8% 11.0% 11.6% 4.4% −0.4% −31.6%
FCF margin 7.0% 6.0% 8.3% 10.7% 12.0% 17.1% 14.3% 4.7% 1.6% −1.9%
Returns
Return on capital 11.5% 5.9% 7.6% 3.7% 7.5% 7.9% 9.8% 4.5% 1.1% −22.0%
Return on capital employed 7.0% 2.0% 3.9% 3.2% 4.9% 5.9% 6.8% 3.2% 0.9% −15.8%
Return on equity 9.4% 7.2% 5.2% 3.6% 9.1% 10.6% 10.4% 4.0% −0.4% −39.9%
Return on assets 4.2% 2.6% 1.9% 1.6% 3.9% 4.6% 4.7% 1.8% −0.2% −13.5%
Growth
Revenue growth 12.4% 19.8% 23.9% 3.1% −9.6% 12.4% 1.0% −1.0% 4.5% 1.5%
Net income growth — −13.2% −6.1% −17.4% 166.7% 26.3% 6.8% −62.5% −110.3% —
EPS growth — −12.8% −12.2% −19.4% 170.7% 26.1% 9.1% −61.1% −110.7% —
FCF growth −3.3% 2.8% 71.7% 32.8% 1.9% 60.3% −16.0% −67.1% −65.8% −224.4%
Share count change 11.0% −0.1% 6.2% 3.0% −1.5% 0.3% −2.3% −3.8% −4.1% −0.4%
Financial health
Net debt / EBITDA −0.5x −1.3x 3.4x 3.3x 1.8x 1.3x 1.1x 2.8x 5.3x —
Debt / equity 0.0x 0.0x 0.7x 0.6x 0.6x 0.5x 0.4x 0.5x 0.5x 0.7x
Interest coverage 4.5x 1.3x 1.7x 1.7x 2.1x 3.9x 4.8x 2.2x 0.4x −5.7x
Current ratio 4.0x 2.4x 3.0x 2.6x 3.1x 3.4x 3.6x 3.5x 1.2x 2.5x
Quick ratio 2.3x 1.5x 1.9x 1.6x 2.3x 2.5x 2.6x 2.2x 0.7x 1.5x
Capital allocation
Capex / revenue 4.8% 3.7% 5.3% 4.6% 2.8% 3.1% 2.7% 4.3% 6.5% 5.0%
Stock comp / revenue 1.7% 1.8% 1.4% 1.4% 1.4% 2.4% 1.8% 1.3% 1.5% 1.1%
Payouts / FCF 0.0% 0.0% 0.0% 0.0% 60.6% 0.0% 56.3% 376.3% 210.2% —
Quality scores
Piotroski F-score 8.0 5.0 4.0 6.0 7.0 7.0 8.0 4.0 5.0 5.0
Altman Z'' 3.1 1.8 2.5 2.4 3.0 3.2 3.5 3.1 1.7 1.2
Accruals ratio −2.3% −2.0% −4.4% −5.7% −2.0% −3.9% −2.2% −1.9% −3.5% −14.8%

Source: SEC EDGAR XBRL filings (CIK 0000917520). Data updated October 23, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open